Johnston P G, Hardisty R M, Kay H E, Smith P G
Br Med J. 1974 Jul 13;3(5923):81-3. doi: 10.1136/bmj.3.5923.81.
Analysis of the remission induction phase in three Medical Research Council trials of treatment of acute lymphoblastic leukaemia has provided evidence of the adverse effect of the combination of colaspase (L-asparaginase) with vincristine and prednisolone. Significant myelosuppression, particularly of the granulocytic series, resulted in an increase in Gram-negative sepsis and death during the neutropenic phase induced by colaspase. The rate of blast-cell regression was increased by colaspase. It is suggested that the introduction of colaspase should be delayed until there is evidence of bone marrow regeneration in order to procure this benefit without the attendant toxicity.
对医学研究委员会三项急性淋巴细胞白血病治疗试验的缓解诱导期分析表明,天冬酰胺酶(L-门冬酰胺酶)与长春新碱和泼尼松龙联合使用存在不良影响。显著的骨髓抑制,尤其是粒细胞系列,导致在天冬酰胺酶诱导的中性粒细胞减少期革兰氏阴性菌败血症和死亡增加。天冬酰胺酶提高了原始细胞消退率。建议推迟使用天冬酰胺酶,直到有骨髓再生的证据,以便在不伴随毒性的情况下获得这种益处。